Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing

L. Gaspar, M. Reich, Z. Kassai, F. Macasek, L. Rodrigo, P. Kruzliak, P. Kovac,

. 2016 ; 6 (3) : 154-65. [pub] 20160706

Language English Country United States

Document type Journal Article

Nine years of experience with 2286 commercial synthesis allowed us to deliver comprehensive information on the quality of (18)F-FDG production. Semi-automated FDG production line using Cyclone 18/9 machine (IBA Belgium), TRACERLab MXFDG synthesiser (GE Health, USA) using alkalic hydrolysis, grade "A" isolator with dispensing robotic unit (Tema Sinergie, Italy), and automatic control system under GAMP5 (minus2, Slovakia) was assessed by TQM tools as highly reliable aseptic production line, fully compliant with Good Manufacturing Practice and just-in-time delivery of FDG radiopharmaceutical. Fluoride-18 is received in steady yield and of very high radioactive purity. Synthesis yields exhibited high variance connected probably with quality of disposable cassettes and chemicals sets. Most performance non-conformities within the manufacturing cycle occur at mechanical nodes of dispensing unit. The long-term monitoring of 2286 commercial synthesis indicated high reliability of automatic synthesizers. Shewhart chart and ANOVA analysis showed that minor non-compliances occurred were mostly caused by the declinations of less experienced staff from standard operation procedures, and also by quality of automatic cassettes. Only 15 syntheses were found unfinished and in 4 cases the product was out-of-specification of European Pharmacopoeia. Most vulnerable step of manufacturing was dispensing and filling in grade "A" isolator. Its cleanliness and sterility was fully controlled under the investigated period by applying hydrogen peroxide vapours (VHP). Our experience with quality assurance in the production of [(18)F]-fluorodeoxyglucose (FDG) at production facility of BIONT based on TRACERlab MXFDG production module can be used for bench-marking of the emerging manufacturing and automated manufacturing systems.

000      
00000naa a2200000 a 4500
001      
bmc16027448
003      
CZ-PrNML
005      
20210121144632.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
035    __
$a (PubMed)27508102
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gaspar, Ludovit $u BIONT, a.s.Bratislava, Slovak Republic; 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University and University HospitalBratislava, Slovak Republic.
245    10
$a Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing / $c L. Gaspar, M. Reich, Z. Kassai, F. Macasek, L. Rodrigo, P. Kruzliak, P. Kovac,
520    9_
$a Nine years of experience with 2286 commercial synthesis allowed us to deliver comprehensive information on the quality of (18)F-FDG production. Semi-automated FDG production line using Cyclone 18/9 machine (IBA Belgium), TRACERLab MXFDG synthesiser (GE Health, USA) using alkalic hydrolysis, grade "A" isolator with dispensing robotic unit (Tema Sinergie, Italy), and automatic control system under GAMP5 (minus2, Slovakia) was assessed by TQM tools as highly reliable aseptic production line, fully compliant with Good Manufacturing Practice and just-in-time delivery of FDG radiopharmaceutical. Fluoride-18 is received in steady yield and of very high radioactive purity. Synthesis yields exhibited high variance connected probably with quality of disposable cassettes and chemicals sets. Most performance non-conformities within the manufacturing cycle occur at mechanical nodes of dispensing unit. The long-term monitoring of 2286 commercial synthesis indicated high reliability of automatic synthesizers. Shewhart chart and ANOVA analysis showed that minor non-compliances occurred were mostly caused by the declinations of less experienced staff from standard operation procedures, and also by quality of automatic cassettes. Only 15 syntheses were found unfinished and in 4 cases the product was out-of-specification of European Pharmacopoeia. Most vulnerable step of manufacturing was dispensing and filling in grade "A" isolator. Its cleanliness and sterility was fully controlled under the investigated period by applying hydrogen peroxide vapours (VHP). Our experience with quality assurance in the production of [(18)F]-fluorodeoxyglucose (FDG) at production facility of BIONT based on TRACERlab MXFDG production module can be used for bench-marking of the emerging manufacturing and automated manufacturing systems.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Reich, Michal $u BIONT, a.s. Bratislava, Slovak Republic.
700    1_
$a Kassai, Zoltan $u BIONT, a.s. Bratislava, Slovak Republic.
700    1_
$a Macasek, Fedor $u BIONT, a.s. Bratislava, Slovak Republic.
700    1_
$a Rodrigo, Luis $u University of Oviedo, Central University Hospital of Asturias (HUCA) Oviedo, Spain.
700    1_
$a Kruzliak, Peter $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic.
700    1_
$a Kovac, Peter $u BIONT, a.s. Bratislava, Slovak Republic.
773    0_
$w MED00190028 $t American journal of nuclear medicine and molecular imaging $x 2160-8407 $g Roč. 6, č. 3 (2016), s. 154-65
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27508102 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20210121144630 $b ABA008
999    __
$a ind $b bmc $g 1165762 $s 952078
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 6 $c 3 $d 154-65 $e 20160706 $i 2160-8407 $m American journal of nuclear medicine and molecular imaging $n Am J Nucl Med Mol Imaging $x MED00190028
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...